Editorial
Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC—is it justified?
Translational Lung Cancer Research
2021;
10
(1)
:1-4
.
(26 January 2021)
Could the clinical target volume be omitted for radiotherapy of locally advanced non-small cell lung cancer in the modern era?
Translational Lung Cancer Research
2021;
10
(1)
:5-8
.
(26 January 2021)
Prognostic models for immunotherapy: emerging factors for an evolving treatment landscape
Translational Lung Cancer Research
2021;
10
(1)
:9-12
.
(26 January 2021)
Endocrine immune-related adverse events: a double-edged sword?
Translational Lung Cancer Research
2021;
10
(1)
:13-17
.
(26 January 2021)
Original Article
Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma
Translational Lung Cancer Research
2021;
10
(1)
:18-31
.
(26 January 2021)
Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma
Translational Lung Cancer Research
2021;
10
(1)
:32-44
.
(26 January 2021)
Association between dietary sodium, potassium intake and lung cancer risk: evidence from the prostate, lung, colorectal and ovarian cancer screening trial and the Women’s Health Initiative
Translational Lung Cancer Research
2021;
10
(1)
:45-56
.
(26 January 2021)
Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression
Translational Lung Cancer Research
2021;
10
(1)
:57-70
.
(26 January 2021)
Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States
Translational Lung Cancer Research
2021;
10
(1)
:71-79
.
(26 January 2021)
A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients
Translational Lung Cancer Research
2021;
10
(1)
:80-92
.
(26 January 2021)
Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study
Translational Lung Cancer Research
2021;
10
(1)
:93-103
.
(26 January 2021)
Genomic profiling of extracellular vesicle-derived DNA from bronchoalveolar lavage fluid of patients with lung adenocarcinoma
Translational Lung Cancer Research
2021;
10
(1)
:104-116
.
(26 January 2021)
Prognostic significance of cribriform adenocarcinoma of the lung: validation analysis of 1,057 Japanese patients with resected lung adenocarcinoma and a review of the literature
Translational Lung Cancer Research
2021;
10
(1)
:117-127
.
(26 January 2021)
Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:128-142
.
(26 January 2021)
Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:143-155
.
(26 January 2021)
Toxicity after volumetric modulated arc therapy for lung cancer: a monocentric retrospective study
Translational Lung Cancer Research
2021;
10
(1)
:156-166
.
(26 January 2021)
A prognostic nomogram for lung adenocarcinoma based on immune-infiltrating Treg-related genes: from bench to bedside
Translational Lung Cancer Research
2021;
10
(1)
:167-182
.
(26 January 2021)
Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
Translational Lung Cancer Research
2021;
10
(1)
:183-192
.
(26 January 2021)
Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study
Translational Lung Cancer Research
2021;
10
(1)
:193-201
.
(26 January 2021)
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
Translational Lung Cancer Research
2021;
10
(1)
:202-220
.
(26 January 2021)
Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:221-232
.
(26 January 2021)
Can autoantibody tests enhance lung cancer screening?—an evaluation of EarlyCDT®-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI)
Translational Lung Cancer Research
2021;
10
(1)
:233-242
.
(26 January 2021)
A preclinical research platform to evaluate photosensitizers for transbronchial localization and phototherapy of lung cancer using an orthotopic mouse model
Translational Lung Cancer Research
2021;
10
(1)
:243-251
.
(26 January 2021)
A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401)
Translational Lung Cancer Research
2021;
10
(1)
:252-260
.
(26 January 2021)
Synergy between early-incorporation immunotherapy and extracranial radiotherapy in metastatic non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:261-273
.
(26 January 2021)
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit
Translational Lung Cancer Research
2021;
10
(1)
:274-278
.
(26 January 2021)
Identifying optimal candidates for primary tumor resection among metastatic non-small cell lung cancer patients: a population-based predictive model
Translational Lung Cancer Research
2021;
10
(1)
:279-291
.
(26 January 2021)
Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients
Translational Lung Cancer Research
2021;
10
(1)
:292-303
.
(26 January 2021)
High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)
Translational Lung Cancer Research
2021;
10
(1)
:304-313
.
(26 January 2021)
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
Translational Lung Cancer Research
2021;
10
(1)
:314-325
.
(26 January 2021)
The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment
Translational Lung Cancer Research
2021;
10
(1)
:326-339
.
(26 January 2021)
cGAS-STING pathway expression as a prognostic tool in NSCLC
Translational Lung Cancer Research
2021;
10
(1)
:340-354
.
(26 January 2021)
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab
Translational Lung Cancer Research
2021;
10
(1)
:355-367
.
(26 January 2021)
MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:368-380
.
(26 January 2021)
Development of a nomogram for predicting the operative mortality of patients who underwent pneumonectomy for lung cancer: a population-based analysis
Translational Lung Cancer Research
2021;
10
(1)
:381-391
.
(26 January 2021)
Association between aspirin use and lung cancer incidence depends on high-frequency use, bodyweight, and age in U.S. adults
Translational Lung Cancer Research
2021;
10
(1)
:392-401
.
(26 January 2021)
Perioperative comparison of video-assisted thoracic surgery and open lobectomy for pT1-stage non-small cell lung cancer patients in China: a multi-center propensity score-matched analysis
Translational Lung Cancer Research
2021;
10
(1)
:402-414
.
(26 January 2021)
Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience
Translational Lung Cancer Research
2021;
10
(1)
:415-429
.
(26 January 2021)
A nomogram for predicting the risk of lymph node metastasis in T1–2 non-small-cell lung cancer based on PET/CT and clinical characteristics
Translational Lung Cancer Research
2021;
10
(1)
:430-438
.
(26 January 2021)
Review Article
Current progress and mechanisms of bone metastasis in lung cancer: a narrative review
Translational Lung Cancer Research
2021;
10
(1)
:439-451
.
(26 January 2021)
Lung cancer screening strategy for non-high-risk individuals: a narrative review
Translational Lung Cancer Research
2021;
10
(1)
:452-461
.
(26 January 2021)
Narrative review: mesenchymal-epithelial transition inhibitors—meeting their target
Translational Lung Cancer Research
2021;
10
(1)
:462-474
.
(26 January 2021)
Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issues
Translational Lung Cancer Research
2021;
10
(1)
:475-482
.
(26 January 2021)
Case Report
Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma: a case report
Translational Lung Cancer Research
2021;
10
(1)
:483-486
.
(26 January 2021)
Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series
Translational Lung Cancer Research
2021;
10
(1)
:487-495
.
(26 January 2021)
Review Articles on Multimodal Management of Locally Advanced N2 Non-small Cell Lung Cancer
Mediastinal staging for non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:496-505
.
(26 January 2021)
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival
Translational Lung Cancer Research
2021;
10
(1)
:506-518
.
(26 January 2021)
Minimal invasive surgery in locally advanced N2 non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:519-528
.
(26 January 2021)
Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:529-538
.
(26 January 2021)
Induction treatment in patients with stage III non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:539-554
.
(26 January 2021)
Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:555-562
.
(26 January 2021)
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:563-580
.
(26 January 2021)
Prognostic factors in potentially resectable stage III non-small cell lung cancer receiving neoadjuvant treatment—a narrative review
Translational Lung Cancer Research
2021;
10
(1)
:581-589
.
(26 January 2021)
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:590-606
.
(26 January 2021)
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
Translational Lung Cancer Research
2021;
10
(1)
:607-621
.
(26 January 2021)
Disclosure:
1. The series “Multimodal management of locally advanced N2 non-small cell lung cancer” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Mariano Provencio served as the unpaid Guest Editor for the series.